- Home
- ELVN vs SYRE Comparison
ELVN vs SYRE Comparison
Compare ELVN & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- SYRE
- Stock Information
- Founded
- ELVN 2016
- SYRE 2013
- Country
- ELVN United States
- SYRE United States
- Employees
- ELVN N/A
- SYRE N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ELVN Health Care
- SYRE Health Care
- Exchange
- ELVN Nasdaq
- SYRE Nasdaq
- Market Cap
- ELVN 1.2B
- SYRE 1.1B
- IPO Year
- ELVN 2020
- SYRE 2016
- Fundamental
- Price
- ELVN $20.52
- SYRE $22.25
- Analyst Decision
- ELVN Strong Buy
- SYRE Strong Buy
- Analyst Count
- ELVN 5
- SYRE 6
- Target Price
- ELVN $41.20
- SYRE $57.60
- AVG Volume (30 Days)
- ELVN 399.0K
- SYRE 1.3M
- Earning Date
- ELVN 11-12-2025
- SYRE 11-06-2025
- Dividend Yield
- ELVN N/A
- SYRE N/A
- EPS Growth
- ELVN N/A
- SYRE N/A
- EPS
- ELVN N/A
- SYRE N/A
- Revenue
- ELVN N/A
- SYRE N/A
- Revenue This Year
- ELVN N/A
- SYRE N/A
- Revenue Next Year
- ELVN $20.05
- SYRE N/A
- P/E Ratio
- ELVN N/A
- SYRE N/A
- Revenue Growth
- ELVN N/A
- SYRE N/A
- 52 Week Low
- ELVN $13.30
- SYRE $10.91
- 52 Week High
- ELVN $29.79
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- ELVN 49.61
- SYRE 66.03
- Support Level
- ELVN $21.08
- SYRE $18.12
- Resistance Level
- ELVN $22.36
- SYRE $24.02
- Average True Range (ATR)
- ELVN 1.00
- SYRE 1.55
- MACD
- ELVN 0.04
- SYRE 0.44
- Stochastic Oscillator
- ELVN 43.98
- SYRE 78.26
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.